Drug Discovery
By
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push the $100 Billion GLP-1 Market Toward More Transparent, Evidence-Based Advertising?
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
Sandoz’s $314M Bet on Chinese Biosimilars Targets a Drug the Industry Couldn’t Crack for a Decade
Inside the Sandoz-Henlius licensing deal for biosimilars of Repatha, Benlysta, and Erbitux — and why one of the…
Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For
What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of personalized cancer vaccines…
